New hope for Tough-to-Treat breast cancer patients
NCT ID NCT06908928
Summary
This early-stage study is testing a new drug called bulumtatug fuvedotin for people with advanced triple-negative breast cancer that has returned or spread. The trial is for patients who have already tried other targeted treatments called antibody-drug conjugates. Researchers want to see if this new drug can shrink tumors and control the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10021, United States
Contact Phone: •••-•••-••••
Contact
-
UCSD Moores Cancer Center
RECRUITINGLa Jolla, California, 92093, United States
Contact Phone: •••-•••-••••
Contact
-
UChicago Medicine Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.